Get the Stockscreener App
27.12
0.33%
0.09
After Hours:
27.12
Pacira Biosciences Inc stock is traded at $27.12, with a volume of 601.75K.
It is up +0.33% in the last 24 hours and up +9.31% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$27.03
Open:
$26.99
24h Volume:
601.75K
Relative Volume:
0.93
Market Cap:
$1.22B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
18.70
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
+2.53%
1M Performance:
+9.31%
6M Performance:
+23.05%
1Y Performance:
+113.04%
1-Day Range:
$26.60
$27.46
1-Week Range:
$25.63
$27.46
52-Week Range:
$12.84
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
27.12 | 1.20B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
51,764 Shares in Pacira BioSciences, Inc. $PCRX Bought by Caxton Associates LLP - MarketBeat
Pacira BioSciences, Inc. $PCRX Shares Acquired by Jacobs Levy Equity Management Inc. - MarketBeat
Pacira BioSciences, Inc. $PCRX Shares Bought by Bridgeway Capital Management LLC - MarketBeat
Alyeska Investment Group L.P. Invests $32.51 Million in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences director Ceesay sells $64,005 in shares By Investing.com - Investing.com Canada
Pacira BioSciences director Ceesay sells $64,005 in shares - Investing.com
Why is Pacira BioSciences Inc. stock going down2025 Institutional Moves & Entry and Exit Point Strategies - beatles.ru
RSI + MACD Show Convergence for Pacira BioSciences Inc.2025 Pullback Review & Free Daily Entry Point Trade Alerts - beatles.ru
Pacira BioSciences (NASDAQ:PCRX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Pacira BioSciences appoints Lauren Riker as interim CFO - MSN
Is Pacira BioSciences Inc. impacted by rising ratesMarket Movement Recap & Community Trade Idea Sharing - classian.co.kr
PDT Partners LLC Sells 41,615 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Automated trading signals detected on Pacira BioSciences Inc.2025 Dividend Review & Real-Time Volume Analysis Alerts - Newser
Predicting Pacira BioSciences Inc. trend using moving averagesJuly 2025 Weekly Recap & Technical Buy Zone Confirmations - Newser
Chart based exit strategy for Pacira BioSciences Inc.Swing Trade & Reliable Intraday Trade Plans - Newser
Tools to assess Pacira BioSciences Inc.’s risk profileBear Alert & Risk Managed Investment Strategies - Newser
Technical signs of recovery in Pacira BioSciences Inc.Fed Meeting & Comprehensive Market Scan Reports - Newser
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira BioSciences: Corporate Governance Reforms and Executive Compensation Alignment in 2025 - AInvest
Does Pacira BioSciences Inc. have strong fundamentalsJuly 2025 Earnings & Fast Moving Trade Plans - خودرو بانک
Pacira BioSciences reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Pacira (PCRX) BioSciences Announces Inducement Awards to New Emp - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listin - GuruFocus
Pacira BioSciences’ Strategic Use of Equity Incentives to Fuel Growth - AInvest
Pacira BioSciences grants inducement awards to nine new employees. - AInvest
31.1K Shares Worth of Equity Awards: Pacira BioSciences Strengthens Team with Nine Strategic Hires - Stock Titan
Visual trend scoring systems applied to Pacira BioSciences Inc.July 2025 Outlook & Consistent Profit Alerts - Newser
Detecting price anomalies in Pacira BioSciences Inc. with AIInflation Watch & Target Return Focused Picks - Newser
Live market analysis of Pacira BioSciences Inc.Treasury Yields & Long-Term Growth Plans - Newser
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Trend analysis for Pacira BioSciences Inc. this weekTrade Entry Report & Real-Time Stock Movement Alerts - Newser
Pacira BioSciences Inc. stock prediction for this weekEarnings Recap Report & Entry Point Confirmation Alerts - Newser
Does Pacira BioSciences Inc. have declining or rising EPSJuly 2025 Snapshot & Weekly High Return Stock Forecasts - خودرو بانک
Can Pacira BioSciences Inc. grow without external funding2025 Short Interest & AI Based Buy and Sell Signals - خودرو بانک
Does Pacira BioSciences Inc. fit your quant trading modelWeekly Stock Report & Low Risk High Win Rate Stock Picks - Newser
What are Pacira BioSciences Inc.’s earnings expectationsJuly 2025 PreEarnings & Short-Term High Return Strategies - خودرو بانک
Using flow based indicators on Pacira BioSciences Inc.Market Rally & Fast Exit Strategy with Risk Control - Newser
Best data tools to analyze Pacira BioSciences Inc. stockM&A Rumor & Safe Swing Trade Setups - Newser
Risk adjusted return profile for Pacira BioSciences Inc. analyzedJuly 2025 Gainers & Safe Capital Growth Stock Tips - Newser
What data driven models say about Pacira BioSciences Inc.’s future2025 Investor Takeaways & Capital Efficiency Focused Strategies - Newser
Institutional scanner results for Pacira BioSciences Inc.July 2025 Sentiment & AI Driven Stock Price Forecasts - Newser
Pacira BioSciences, Inc. $PCRX is Doma Perpetual Capital Management LLC's Largest Position - MarketBeat
Exit strategy if you’re trapped in Pacira BioSciences Inc.July 2025 Spike Watch & Precise Swing Trade Entry Alerts - Newser
Pacira BioSciences Inc. stock trend forecastJuly 2025 Big Picture & Low Drawdown Trading Techniques - Newser
Reversal indicators forming on Pacira BioSciences Inc. stockQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser
Candlestick signals on Pacira BioSciences Inc. stock todayShare Buyback & Verified Trade Idea Suggestions - Newser
Has Pacira BioSciences Inc. formed a bullish divergenceJuly 2025 Spike Watch & Community Consensus Trade Signals - Newser
Published on: 2025-09-03 02:53:04 - Newser
Is Pacira BioSciences Inc. stock a value trapQuarterly Trade Summary & Consistent Growth Equity Picks - خودرو بانک
Signal strength of Pacira BioSciences Inc. stock in tech scannersEarnings Performance Report & Weekly Sector Rotation Insights - Newser
How to forecast Pacira BioSciences Inc. trends using time seriesJuly 2025 Levels & Risk Controlled Daily Plans - Newser
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):